Learn More
Description
The MRα4-1 antibody reacts with the integrin α4 chain, which is expressed as a heterodimer with either of two β chains, β1 or β7. The α4β1 integrin (VLA-4, CD49d/CD29) is expressed on peripheral T and B lymphocytes, thymocytes, and monocytes| while the α4β7 integrin (LPAM-1) is expressed on peripheral lymphocytes. These integrins mediate a variety of cell-cell and cell-matrix interactions, recognizing the ligands CD106 (VCAM-1), MAdCAM-1, and fibronectin. It has been reported that soluble mAb MRα4-1 partially inhibits in vitro binding of VCAM-1 and mast cells to fibronectin and inhibits the enhanced degranulation of IgE-sensitized RBL-2H3 basophilic leukemia cell line induced on fibronectin-coated plates. Furthermore, plate-bound MRα4-1 antibody enhances the degranulation of IgE-sensitized RBL-2H3 cells| and subcutaneous injection of MRα4-1 mAb, along with anti-CD49e and anti-CD61 antibodies, inhibits experimentally induced passive cutaneous anaphylaxis.
Specifications
Specifications
| Antigen | CD49d |
| Applications | Flow Cytometry |
| Classification | Monoclonal |
| Clone | MRA4-1 |
| Conjugate | R718 |
| Host Species | Mouse |
| Quantity | 50 μg |
| Regulatory Status | RUO |
| Primary or Secondary | Primary |
| Target Species | Rat |
| Show More |
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.